Insmed (INSM) Competitors $75.57 +1.87 (+2.54%) As of 11:54 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends INSM vs. TAK, ALNY, ONC, RPRX, TEVA, GMAB, UTHR, ITCI, BMRN, and SMMTShould you be buying Insmed stock or one of its competitors? The main competitors of Insmed include Takeda Pharmaceutical (TAK), Alnylam Pharmaceuticals (ALNY), Beigene (ONC), Royalty Pharma (RPRX), Teva Pharmaceutical Industries (TEVA), Genmab A/S (GMAB), United Therapeutics (UTHR), Intra-Cellular Therapies (ITCI), BioMarin Pharmaceutical (BMRN), and Summit Therapeutics (SMMT). These companies are all part of the "pharmaceutical preparations" industry. Insmed vs. Takeda Pharmaceutical Alnylam Pharmaceuticals Beigene Royalty Pharma Teva Pharmaceutical Industries Genmab A/S United Therapeutics Intra-Cellular Therapies BioMarin Pharmaceutical Summit Therapeutics Takeda Pharmaceutical (NYSE:TAK) and Insmed (NASDAQ:INSM) are both large-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, community ranking, dividends, risk, institutional ownership, valuation, profitability, media sentiment and analyst recommendations. Is TAK or INSM more profitable? Takeda Pharmaceutical has a net margin of 4.53% compared to Insmed's net margin of -251.24%. Takeda Pharmaceutical's return on equity of 9.39% beat Insmed's return on equity.Company Net Margins Return on Equity Return on Assets Takeda Pharmaceutical4.53% 9.39% 4.53% Insmed -251.24%-4,773.73%-54.58% Do analysts prefer TAK or INSM? Insmed has a consensus target price of $93.33, suggesting a potential upside of 26.64%. Given Insmed's stronger consensus rating and higher possible upside, analysts clearly believe Insmed is more favorable than Takeda Pharmaceutical.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Takeda Pharmaceutical 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Insmed 0 Sell rating(s) 0 Hold rating(s) 16 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media prefer TAK or INSM? In the previous week, Insmed had 8 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 15 mentions for Insmed and 7 mentions for Takeda Pharmaceutical. Takeda Pharmaceutical's average media sentiment score of 0.95 beat Insmed's score of 0.66 indicating that Takeda Pharmaceutical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Takeda Pharmaceutical 4 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Insmed 7 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Which has better valuation & earnings, TAK or INSM? Takeda Pharmaceutical has higher revenue and earnings than Insmed. Insmed is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTakeda Pharmaceutical$4.58T0.01$994.06M$0.4037.24Insmed$363.71M36.68-$749.57M-$5.59-13.18 Does the MarketBeat Community prefer TAK or INSM? Insmed received 454 more outperform votes than Takeda Pharmaceutical when rated by MarketBeat users. Likewise, 66.75% of users gave Insmed an outperform vote while only 56.82% of users gave Takeda Pharmaceutical an outperform vote. CompanyUnderperformOutperformTakeda PharmaceuticalOutperform Votes10056.82% Underperform Votes7643.18% InsmedOutperform Votes55466.75% Underperform Votes27633.25% Which has more risk & volatility, TAK or INSM? Takeda Pharmaceutical has a beta of 0.46, indicating that its share price is 54% less volatile than the S&P 500. Comparatively, Insmed has a beta of 1.28, indicating that its share price is 28% more volatile than the S&P 500. Do institutionals and insiders believe in TAK or INSM? 9.2% of Takeda Pharmaceutical shares are owned by institutional investors. 0.0% of Takeda Pharmaceutical shares are owned by insiders. Comparatively, 4.6% of Insmed shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. SummaryTakeda Pharmaceutical and Insmed tied by winning 9 of the 18 factors compared between the two stocks. Remove Ads Get Insmed News Delivered to You Automatically Sign up to receive the latest news and ratings for INSM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart INSM vs. The Competition Export to ExcelMetricInsmedPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$13.23B$7.01B$5.67B$8.01BDividend YieldN/A2.71%4.89%4.03%P/E Ratio-13.186.1923.8618.90Price / Sales36.68217.80382.37118.46Price / CashN/A65.6738.0534.62Price / Book-31.776.476.844.18Net Income-$749.57M$139.77M$3.19B$246.59M7 Day Performance-4.96%-1.67%-2.26%-3.09%1 Month Performance-7.41%-7.16%-7.20%-8.97%1 Year Performance169.86%-8.58%8.72%0.74% Insmed Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)INSMInsmed4.2695 of 5 stars$75.57+2.5%$93.33+23.5%+172.2%$13.70B$363.71M-13.54373TAKTakeda Pharmaceutical2.6201 of 5 stars$15.05-0.8%N/A+2.2%$47.90B$4.58T37.6449,281ALNYAlnylam Pharmaceuticals4.579 of 5 stars$236.73-3.2%$304.26+28.5%+60.1%$30.77B$2.25B-109.532,230Analyst ForecastAnalyst RevisionPositive NewsONCBeigene2.219 of 5 stars$243.08-1.6%$327.00+34.5%N/A$23.79B$3.81B-29.5010,600RPRXRoyalty Pharma4.9376 of 5 stars$32.78-0.7%$41.60+26.9%+7.9%$18.92B$2.26B22.6480Positive NewsTEVATeva Pharmaceutical Industries2.8916 of 5 stars$14.67-4.5%$23.43+59.8%+20.8%$16.63B$16.54B-10.1136,830GMABGenmab A/S4.0144 of 5 stars$22.21-8.0%$42.17+89.9%-36.0%$14.68B$21.53B12.752,204Analyst ForecastShort Interest ↑Analyst RevisionNews CoveragePositive NewsGap UpHigh Trading VolumeUTHRUnited Therapeutics4.8413 of 5 stars$317.51+0.5%$388.25+22.3%+22.0%$14.32B$2.88B14.001,168Positive NewsITCIIntra-Cellular Therapies3.6116 of 5 stars$131.25+0.0%$106.08-19.2%+100.6%$13.95B$680.50M-150.84560Analyst ForecastPositive NewsBMRNBioMarin Pharmaceutical4.9811 of 5 stars$72.09-0.2%$94.00+30.4%-18.0%$13.81B$2.85B32.913,401Analyst UpgradePositive NewsSMMTSummit Therapeutics1.8686 of 5 stars$17.44-1.9%$34.63+98.5%+330.2%$12.91B$700,000.00-62.49110Analyst ForecastPositive NewsGap Up Remove Ads Related Companies and Tools Related Companies Takeda Pharmaceutical Competitors Alnylam Pharmaceuticals Competitors Beigene Competitors Royalty Pharma Competitors Teva Pharmaceutical Industries Competitors Genmab A/S Competitors United Therapeutics Competitors Intra-Cellular Therapies Competitors BioMarin Pharmaceutical Competitors Summit Therapeutics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:INSM) was last updated on 3/12/2025 by MarketBeat.com Staff From Our PartnersURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredFormer CIA to Trump – Will you Shut down this secret lab?Deep in the sands of New Mexico lies a government lab so secret it makes Area 51 look like a tourist spot… ...Paradigm Press | SponsoredDeFi Coin on Verge of Breakout!We’re Opening the Ultimate Crypto Vault… Don't let this be the missed opportunity you regret for years. Crypto 101 Media | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredTrump doesn’t give a damnPorter Stansberry: “I met with Trump’s biggest backers… they’re scooping up these 10 stocks” I recently met...Porter & Company | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | SponsoredTrump’s Victory Could Spark Major Gains for Gold – Don’t Miss Out This "Patriot's Tax Shield" lets you defend your wealth with real, solid gold. Our exclusive, free wealth pr...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Insmed Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Share Insmed With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
